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ABSTRACT 
Background: 
There are no studies of autonomic function comparing Alzheimer’s disease (AD), 
Vascular dementia (VAD), Dementia with Lewy Bodies (DLB) and Parkinson’s 
disease dementia (PDD).  
Aims: 
To assess cardiovascular autonomic function in 39 AD patients, 30 VAD, 30 DLB, 40 
PDD and 38 elderly controls by Ewing’s battery of autonomic function tests and 
power spectral analysis of heart rate variability. To determine the prevalence of 
orthostatic hypotension and autonomic neuropathies by Ewing’s classification. 
Results:  
There were significant differences in severity of cardiovascular autonomic 
dysfunction between the four types of dementia. PDD and DLB had considerable 
dysfunction. VAD showed limited evidence of autonomic dysfunction, and in AD, 
apart from orthostatic hypotension, autonomic functions were relatively unimpaired.  
PDD showed consistent impairment of both parasympathetic and sympathetic 
function tests in comparison with controls (all p<0·001), and AD (all p<0·03). DLB 
showed impairment of parasympathetic function (all p<0.05) and one of the 
sympathetic tests in comparison with controls (orthostasis; p=0·02). PDD had 
significantly more impairment than DLB in some autonomic parameters (Valsalva 
ratio–p=0·024, and response to isometric exercise–p=0·002). VAD patients showed 
impairment in two parasympathetic tests (orthostasis; p=0.02, Valsalva ratio p=0.08) 
and one sympathetic test (orthostasis; p=0.04). These results were in contrast to AD 
patients who only showed impairment in one sympathetic response (orthostasis; 
p=0.004).  
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The prevalence of orthostatic hypotension and autonomic neuropathies was higher in 
all dementias than in controls (all p<0.05). 
 
Conclusion: 
Autonomic dysfunction occurs in all common dementias but is especially prominent 
in PDD with important treatment implications.  
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INTRODUCTION 
Patients with autonomic failure experience disabling postural dizziness, syncope, falls, 
constipation and incontinence.[1] There is a need to identify symptomatic 
dysautonomia in dementia in order to ensure appropriate management and reduce risk 
of falls, which is particularly important as falls are a significant cause of increased 
morbidity, institutionalisation and mortality in these individuals.[2]  
There are no previous prospective studies of autonomic function comparing the most 
common dementia subtypes in the elderly; Alzheimer’s disease (AD), Vascular 
dementia (VAD), Dementia with Lewy Bodies (DLB) and Parkinson’s disease 
dementia (PDD).  A generalised deficit in cholinergic function would be expected to 
lead to autonomic dysfunction and the common dementias have all been associated 
with underactivity of the cholinergic nervous systems.[3] The Braak staging of 
Parkinson’s disease[4] emphasises early involvement of the brainstem, including the 
dorsal vagal nucleus, and autonomic failure is a feature of Parkinson’s disease.[5]  
The only previous studies using standard bedside clinical autonomic tests have mainly 
included patients with AD only,[6-10] although two have included patients with 
multi–infarct dementia or Binswanger’s encephalopathy, [11,12] and there is one 
retrospective report of clinical autonomic dysfunction in DLB patients.[13] Studies 
using bedside tests do require a level of cooperation by the subject which may not be 
possible in dementia. These data can be enhanced by measurements of heart rate 
variability,[14] which requires less cooperation from the subject than other autonomic 
function tests and is suitable for use in patients with dementia.[15] 
We examined autonomic function using a combination of standardized bedside 
clinical testing and heart rate variability techniques, in an unselected series of patients 
with a range of dementia subtypes, diagnosed according to well validated diagnostic 
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criteria, in comparison with appropriately matched elderly controls.  Given the 
evidence of the retrospective study of DLB patients and evidence regarding 
autonomic dysfunction in Parkinson’s disease (PD),[5] we hypothesised that 
autonomic dysfunction would be more severely impaired in DLB and PDD than in 
AD, and that the most severe impairment would be present in PDD due to the length 
of illness and severity of neurodegenerative disease. 
 
METHODS 
Participant recruitment and inclusion criteria 
Consecutive patients were recruited from Neurology, Old Age Psychiatry and 
Geriatric Medical Services within the Northern Region of the United Kingdom. All 
participants were over 65 years of age. AD patients met the NINCDS ADRDA criteria 
for Alzheimer’s disease[16] and Vascular Dementia (VAD) patients met the NINDS 
AIREN criteria for Vascular Dementia.[17] DLB patients met consensus criteria for 
Dementia with Lewy bodies.[18] Parkinson’s disease with dementia patients (PDD) 
met both UKPDS Brain bank criteria[19] and DLB consensus criteria, with motor 
disorder preceding dementia by at least 12 months. An age matched healthy control 
group was recruited by local advertisement. The study received ethical approval from 
the Joint Ethics Committee of Newcastle and North Tyneside Health Authority, the 
University of Newcastle upon Tyne and the University of Northumbria at Newcastle. 
Participants gave consent in accordance with the declaration of Helsinki, with the 
involvement of caregivers and next of kin as described in detail in our previous 
studies in dementia.[20] 
Exclusion criteria 
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Participants were excluded if they were in atrial fibrillation or had other arrhythmias. 
Controls were excluded if they had any evidence of dementia or Parkinson’s disease. 
Clinical Assessment  
All patients received a full medical assessment, including physical examination and 
12 lead electrocardiogram. Significant medical causes of dementia were excluded 
during diagnostic investigations. Duration of dementia, drug history and history of 
hypertension or diabetes mellitus were recorded. Cognitive function was assessed 
using the cognitive subsection of the Cambridge Examination for Mental disorders in 
the elderly (CAMCOG) [21]. All assessments took place in the morning; participants 
were asked to take their usual medications including dopaminergic agents, and to 
refrain from drinking caffeinated drinks or smoking on the morning on the assessment. 
Extra–pyramidal signs were evaluated using the motor subsection of the Unified 
Parkinson’s disease rating scale (UPDRS),[22] after taking the usual dose of levodopa, 
if applicable.  
Clinical Autonomic Function Tests 
Clinical autonomic function tests were carried out according to Ewing’s battery.[23] 
The electrocardiogram (ECG) was recorded during supine rest using standard limb 
leads I or II and locally developed software, sampling at 1 kHz. Blood pressure was 
monitored using a digital photoplethysmograph (Portapres, TNO, Amsterdam) which 
enables non invasive beat to beat blood pressure measurement. Blood pressure data 
were synchronised to ECG and inspected off line for artefacts, ectopic beats and non 
systolic waveforms which were removed using a semi–automated technique. 
Participants rested in the supine position for 10 minutes before starting the tests and 
also rested for 2 minutes between each test. Heart rate tests were excluded if 
invalidated by excessive ectopic activity or other arrhythmia. Blood pressure tests 
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were excluded if the trace was obscured by movement artefact. 
Parasympathetic tests 
1. Deep breathing 
Respiratory sinus arrhythmia was assessed by the performance of 6 deep breaths at a 
frequency of 0·1 Hz. Participants were given adequate rehearsal to achieve the 
required frequency and counted through the 6 breaths. The response was taken as the 
mean of the differences between the maximum and minimum instantaneous heart rate 
for each cycle. A minimum of 3 breaths was required for inclusion. 
2. Orthostasis 
Orthostatic blood pressure and heart rate changes were assessed during a 3 minute 
active stand. Heart rate response to standing was assessed as the ratio of maximum R–
R interval at or around the 30th beat to the minimum R–R interval at or around the 15th 
beat.  
3. Valsalva ratio 
The Valsalva manoeuvre was performed for 15 seconds, requiring forced expiration 
against an open glottis at a pressure of 40 mmHg. The pressure achieved was 
monitored via the PC and visual feedback was available to the participant to enable 
them to maintain a constant pressure. The manoeuvre was performed three times in 
order to maximise participant compliance and ensure reproducibility. The best 
response was used for analysis and a minimum of 12 seconds was required for 
inclusion. 
Valsalva ratio was taken as the maximum R–R interval in the 15 seconds following 
expiration divided by the minimum R–R interval during the manoeuvre.  
Sympathetic tests 
1. Orthostasis 
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Orthostatic blood pressure change was calculated as the difference between the nadir 
blood pressure immediately after standing and the mean blood pressure for the 20 
beats immediately prior to standing. 
2. Valsalva manoeuvre 
Blood pressure response was taken as the difference between the peak systolic blood 
pressure achieved during phase IV and the mean systolic blood pressure for the 20 
beats immediately prior to the manoeuvre. 
3. Isometric exercise  
This was performed by rising from the supine to a sitting position, and remaining in 
that position for 3 minutes, without external help. The blood pressure response was 
taken as the difference between the mean diastolic blood pressure for the 20 beats 
immediately prior to sitting and the 20 beats immediately prior to the end of the sitting 
exercise. A minimum of 90 seconds was required for inclusion. 
Measurement of Heart Rate Variability 
ECG was recorded as described above. Five minutes of RR interval data were 
digitised and stored on computer for subsequent off–line analysis (Lab View and data 
acquisition card 1200, National Instruments, Newbury). Non sinus beats were 
removed automatically, then manually if necessary, using an R wave detection 
software package: the program interpolated an R wave for missed or ectopic beats.[24] 
The record was excluded if excessive ectopic activity or any period of 
supraventricular arrhythmia were present. Power spectral analysis (Fast Fourier 
transformation) of the edited recording was performed to obtain spectral bands in the 
very low (<0·04Hz), low (0·04–0·15Hz) and high (0·15–0·40Hz) frequency bands and 
also total spectral power (<0·40Hz) according to international guidelines.[14] 
Sympathovagal balance was examined by low frequency: high frequency ratio.  
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Orthostatic hypotension 
Sustained orthostatic hypotension was defined as a fall in systolic blood pressure of 
greater than 20 mm Hg or diastolic blood pressure of greater than 10 mm Hg which 
did not return to baseline within 30 seconds from the start of the active stand. Time of 
return to baseline was defined as the start of the first series of 3 consecutive beats in 
the blood pressure which were within one standard deviation of the baseline blood 
pressure.  
Ewing classification of autonomic failure 
Results for each bedside autonomic test were classified as normal or abnormal. A test 
was deemed to be abnormal if the result was below the 5th percentile for that test in 
the control group, and borderline if below the 10th percentile. Ewing’s classification of 
autonomic function[23] was determined as shown below for each patient who had 
complied with sufficient tests for the classification scheme to be applied. 
 
Normal:  all tests normal or 1 borderline 
Early:  one of the 3 heart rate tests abnormal or 2 borderline 
Definite:  two or more of the heart rate tests abnormal 
Severe:  two or more of the heart rate tests abnormal plus one or both of the 
BP tests abnormal or both borderline 
Atypical:  any other combination 
 
Statistics 
Fisher’s Exact test was used to detect the presence of differences across groups in the 
categorical baseline characteristics (gender, history of hypertension, diabetes mellitus, 
levodopa or cardiovascular drug usage). ANOVA was used to compare differences 
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across groups in normally distributed data (age, CAMCOG, levodopa dose). Duration 
of dementia, number of cardiovascular medications and UPDRS score data were not 
normally distributed, therefore, Kruskal–Wallis tests were used to test for differences 
across groups and Mann–Whitney U test to compare differences between individual 
groups.  
Univariate ANOVA analyses were used to establish the presence of significant 
differences in autonomic function tests across diagnostic groups. Heart rate variability 
data were transformed using the natural logarithm to produce a normal distribution. 
Cox regression was used to compare time of return to baseline systolic blood pressure 
as this was a censored event, and Fisher’s Exact tests were used to compare 
categorical outcomes (orthostatic hypotension, Ewing classification).  On the basis of 
our prior hypotheses, if significant differences across groups were present predefined 
comparisons between groups were made (univariate ANOVA or Pearson’s Chi 
squared as appropriate). These compared each disease group with the control group, 
the DLB and PDD groups with the AD group and the DLB group with the PDD group. 
Post hoc multivariate linear regression analyses were performed to examine the 
potential confounding effects of age, gender, duration of dementia, hypertension, 
diabetes and cardiovascular medications.  
All statistical tests were performed using SPSS version 11.0 statistics package. 
Significance was taken as p <0·05. 
 
RESULTS 
Participant characteristics 
One hundred and ninety eight participants met the initial inclusion criteria (42 
controls, 40 AD, 38 VAD, 32 DLB and 46 PDD). Twenty one participants were 
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excluded because of an arrhythmia (16 atrial fibrillation (3 controls, 1 AD, 8 VAD 
and 4 PDD) and 5 other arrhythmia (1 control, 2 DLB and 2 PDD)). One hundred and 
seventy seven participants suitable for analysis remained (38 controls, 39 AD, 30 
VAD, 40 PDD and 30 DLB). 
Table 1 shows the baseline characteristics of the participants. There were no 
differences in gender between groups (all p>0·05). VAD patients were older than 
controls (mean difference 3·9 +/–1·6 years, p=0·002), and PDD patients were younger 
than controls (mean difference 3·9 +/–1·4 years, p=0·007). Patients with VAD had a 
shorter duration of dementia than those in the AD or PDD groups (p=0·002, 0·008 
respectively). All dementia groups had lower CAMCOG scores than controls (all 
p<0·001) but the dementia groups were not different from one another. 
Hypertension was more common in VAD than in all other groups and less common in 
DLB than in controls (VAD vs. other groups all p<0·01, control vs. DLB p=0·017), 
but there were no significant differences between groups in other factors potentially 
affecting autonomic function. All patient groups had higher UPDRS scores than 
controls (all p< 0·001).  
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TABLE 1: PARTICIPANT CHARACTERISTICS 
Diagnosis  
(n) 
CONTROL 
(38) 
AD 
(39) 
VAD 
(30) 
DLB 
(30) 
PDD 
(40) 
Gender: number of males (%)  
χ
2: p=0.222 18 (47) 17 (44) 21 (70) 17 (57) 23 (58) 
Mean Age: years (SD)  
ANOVA: p<0·001 76 (7) 79 (6) 80 (6) 75 (7) 72 (5) 
Median Duration of Dementia (months) 
(IQR) 
 Kruskall Wallis: p=0.014 
– 32 (17–48) 15 (8–28) 21 (12–44) 26 (17–51) 
Mean CAMCOG score (SD)  
ANOVA: p<0·001 93·9 (4·7) 59·4 (14·8) 63·4 (19·0) 60·5 (15·1) 64·4 (16·8) 
Hypertension: present (%)  
χ
2: p<0.001 15 (39) 8 (20) 22 (74) 4 (13) 10 (25) 
Diabetes mellitus: present (%) 
χ
2: p=0.722 2 (5·2) 3 (8) 4 (13) 2 (7) 2 (5) 
Number (%) receiving cardiovascular 
medications 
χ
2: p=0.532 
18 (47)  26 (51)  17 (57)  16 (53)  21 (53)  
Median number of cardiovascular drugs 
(range) 
Kruskall Wallis: p=0.747 
0 (0–2) 1(0–3) 1 (0–3) 1 (0–2) 1(0–3) 
Number (%) receiving levodopa therapy 
χ
2: p<0.001 
Mean daily dose (mg)  
0 (0)– 0 (0)– 1 (3) 150 6 (20) 225 38 (95) 447 
Median UPDRS III score (IQR)  
Kruskall Wallis: p<0.001 1 (0–3) 7 (3–9) 10 (7–17) 29 (14–40) 37 (30–45) 
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Legend to Table 1 
SD: Standard deviation; IQR: Inter–quartile range; PDD: Parkinson’s disease dementia; DLB: Dementia with Lewy bodies; VAD: Vascular 
dementia; AD: Alzheimer’s disease 
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Clinical autonomic testing: Parasympathetic tests 
Patients with PDD had impairment of all parasympathetic tests in comparison with 
controls in univariate ANOVA (table 2). Patients with DLB had impaired heart rate 
responses to deep breathing and standing in comparison with controls in univariate 
ANOVA (p=0·001, 0·048 respectively). All parasympathetic tests were significantly 
impaired in both PDD and DLB in comparison with controls in a multivariate analysis 
adjusting for age, gender, diabetes, hypertension and cardiovascular medications. 
Patients with VAD had impaired heart rate responses to standing and Valsalva 
manoeuvre in comparison with controls (p=0·017, p=0·008 respectively), but only the 
difference in Valsalva ratio remained significant in multivariate analyses (p=0·04). 
There were no significant differences in parasympathetic tests between AD patients 
and the control group.  
PDD patients were more impaired in comparison with AD patients on all 
parasympathetic tests (all p<0·05). DLB patients had more impaired heart rate 
responses to deep breathing in comparison with AD patients (p=0·003).  In 
multivariate analyses, both DLB and PDD patient groups were more impaired in 
comparison with AD patients on all parasympathetic tests (all p<0·05), except DLB vs. 
AD on response to standing (p=0.071). PDD patients had a more impaired Valsalva 
ratio than DLB patients (p=0·024) and this difference remained in multivariate 
analyses (p=0·014). 
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TABLE 2: PARASYMPATHETIC CLINICAL AUTONOMIC FUNCTION TESTS 
 
Legend to Table 2 
P values in the left hand column give the result of the univariate ANOVA across all groups.  
Columns 3–6: show the mean (95% confidence intervals for the mean) for each parasympathetic test by diagnosis, with p values for that patient 
group in comparison with the control group in univariate ANOVA, and in multivariate analyses in brackets.  
The results of other predefined contrasts are given in the right hand column.  
All significant results are shown in boldface.
Diagnosis CONTROL  AD  VAD  DLB  PDD   
Mean change in 
heart rate during 
deep breathing 
ANOVA: p=0·002 
8·15 (6·48–9·82) 7·21 (5·60–8·83) 
0·42 (0.75) 
6·01 (4·31–7·71) 
0·07 (0.16) 
4·28 (3·20–5·37) 
0·001 (0.001) 
3·98 (3·08–6·29) 
0·003 (0.001) 
AD vs. DLB: 0·003 (0.01)  
AD vs. PDD: 0·03 (0.04) 
DLB vs. PDD: 0·67 (0.89) 
Mean heart rate 
response to standing 
ANOVA: p=0·001 
1·15 (1·12–1·19)  1·13 (1·08–1·18) 
0·51 (0.86) 
1·09 (1·06–1·13) 
0·02 (0.14) 
1·10 (1·05–1·14) 
0·05 (0.02) 
1·05 (1·03–1·07) 
0·001 (0.001) 
AD vs. DLB: 0·25 (0.07)    
AD vs. PDD: 0·002 (0.003)    
DLB vs. PDD: 0·07 (0.04) 
Mean Valsalva Ratio 
ANOVA: p<0·001 
1·43 (1·32–1·54) 1·38 (1·29–1·47) 
0·447 (0.863) 
1·26 (1·19–1·33) 
0·008 (0.04) 
1·28 (1·18–1·39) 
0·05  (0.04) 
1·15 (1·12–1·19) 
0·001 (0.001) 
AD vs. DLB: 0·16 (0.008)  
AD vs. PDD: 0·001 (0.001)    
DLB vs. PDD: 0·02 (0.01) 
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Clinical autonomic testing: Sympathetic tests 
All patient groups had a greater fall in blood pressure upon standing than controls, 
remaining significant in multivariate analyses (all p<0·05) (table 3).  
PDD patients had reduced blood pressure responses to Valsalva manoeuvre and 
isometric exercise in comparison with controls (p<0·001), but other patient groups did 
not.  PDD patients also had reduced blood pressure responses to Valsalva manoeuvre 
and isometric exercise in comparison with AD patients (p<0·01), and reduced 
response to isometric exercise in comparison with DLB patients (p=0·002). DLB 
patients had reduced blood pressure responses to Valsalva manoeuvre in comparison 
with AD patients (p=0·044). None of these findings changed in multivariate analyses. 
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TABLE 3: SYMPATHETIC CLINICAL AUTONOMIC FUNCTION TESTS 
Diagnosis (n) CONTROL  AD VAD  DLB PDD   
Mean fall in systolic blood 
pressure on standing (mm 
Hg)  ANOVA: p=0·01 
26·6 (19·4–33·8)  45·5 (35·1–55·9) 
0·004 (0.03) 
40·9 (28·2–53·5) 
0·04 (0.04) 
43·2 (32·0–54·6) 
0·02 (0.02) 
48·2 (39·7–56·7) 
0·001 (0.005) 
AD vs. DLB: 0·75 (0.78)  
AD vs. PDD  0·68 (0.29)  
DLB vs. PDD: 0·49 (0.37) 
Mean change in systolic 
blood pressure during phase 
IV of Valsalva manoeuvre 
(mm Hg) ANOVA: p=0·002  
16·5 (9·33–23·6) 20·0 (11·1–28·9) 
0·54 (0.08) 
13·4 (5·59–21·2) 
0·56 (0.81) 
7·92 (–0·109–16·0) 
0·11 (0.11) 
0·792 (–3·30–4·89) 
0·001 (0.001) 
AD vs. DLB: 0·04 (0.005) 
AD vs. PDD: 0·001 (0.001) 
DLB vs. PDD: 0·11 (0.12) 
Mean change in diastolic 
blood pressure on isometric 
exercise (mmHg) ANOVA: 
p=0·001 
17·2 (12·7–21·7) 15·5 (10·7–20·4) 
0·611 (0.86) 
12·7 (8·33–17·1) 
0·15 (0.17) 
15·4 (10·7–20·2) 
0·59 (0.30) 
4·67 (–0·22–9·56) 
0·001 (0.001) 
AD vs.· DLB: 0·98 (0.80) 
AD vs. PDD: 0·002 (0.002) 
DLB vs. PDD: 0·002 (0.004) 
 
Legend to Table 3 
P values in the left hand column give the result of the univariate ANOVA across all groups  
Columns 3–6: show the mean (95% confidence intervals for the mean) for each sympathetic test by diagnosis, with p values for that patient 
group in comparison with the control group in univariate ANOVA, and in multivariate analyses in brackets.  
The results of other predefined contrasts are given in the right hand column. All significant results are shown in boldface.  
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Heart Rate Variability 
ANOVA analyses across all groups showed significant differences in total spectral 
power, low frequency band and high frequency band (p=0·040, 0·041, 0·003 
respectively, table 4). There were no differences across groups in mean R–R interval, 
very low frequency band and low frequency: high frequency ratio (p= 0·372, 0·113, 
0·428, respectively).  
Total spectral power, low frequency power and high frequency power were reduced in 
PDD patients in comparison with healthy controls; differences remaining in 
multivariate analyses (all p< 0·05). Total spectral power, low frequency band and high 
frequency band were also reduced in comparison with the AD patient group. DLB 
patients were not significantly different from controls in univariate ANOVA but the 
low frequency band was significantly reduced in multivariate analyses (p=0·021).  
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 TABLE 4: HEART RATE VARIABILITY  
 
Legend to Table 4 
P values in the left hand column give the result of the univariate ANOVA across all groups.  
Columns 3–6: show the mean (95% confidence intervals for the mean) for each heart rate variability test by diagnosis, with p values for that 
patient group in comparison with the control group in univariate ANOVA, and in multivariate analyses in brackets.  
The results of other predefined contrasts are given in the right hand column.  
All significant results are shown in boldface. 
Diagnosis (n) CONTROL (31/38) AD (32/39) VAD (27/30) DLB (23/30) PDD (38/40) 
 
Total Power (ms2) 
ANOVA: p=0·04 
1003 (575–1431) 820 (483–1158) 
0·49 (0.55) 
922 (332–1512) 
0·27 (0.19) 
617 (300–934) 
0·08 (0.05) 
628 (301–714) 
0·003 (0.003) 
AD vs. DLB: 0·24 (0.18)  
AD vs. PDD: 0·02 (0.02)  
DLB vs. PDD: 0·38 (0.42) 
Low Frequency Power 
(ms2)  
ANOVA: p=0·04 
2323 (169–477) 1324 (158–490) 
0·41 (0.43) 
389 (91·5–687) 
0·32 (0.29) 
261 (85·6–438) 
0·059 (0.02) 
171 (94·0–247) 
0·007 (0.002) 
AD vs. DLB: 0·25 (0.13)  
AD vs. PDD: 0·06 (0.03) 
DLB vs. PDD: 0·61 (0.47) 
High Frequency Power 
(ms2)  
ANOVA: p=0·003 
293 (81·3–504) 165 (99·1–232) 
0·89 (0.83) 
231 (54·4–407) 
0·59 (0.39) 
129 (46·5–212) 
0·10 (0.23) 
105 (44·0–166) 
0·001 (0.01) 
AD vs. DLB: 0·13 (0.20)  
AD vs. PDD: 0·001 (0.01) 
DLB vs. PDD: 0·17 (0.25) 
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Orthostatic hypotension 
Sustained orthostatic hypotension was more prevalent in all four patient groups than 
in controls (all p<0·05, table 5). Consistent with this, time for blood pressure to return 
to baseline after standing was significantly longer for AD, DLB and PDD in 
comparison with controls, remaining significant in multivariate analyses.  
Ewing classification 
Table 6 shows the number of cases with each Ewing classification of autonomic 
neuropathy by diagnostic group, and the total number of cases (%)with definite, 
atypical or severe autonomic neuropathy. In comparison with controls, all patient 
groups were more likely to have an autonomic neuropathy and severe, definite and 
atypical autonomic neuropathy than controls (all p<0·05). PDD patients were more 
likely to have an autonomic neuropathy than other patient groups (AD: p=0·001, VAD: 
p=0·024, DLB: p=0·024).  
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TABLE 5: PREVALENCE OF ORTHOSTATIC HYPOTENSION 
Diagnosis CONTROL 
n=38 
AD          
n=38 
VAD     
n=29 
DLB          
n=27 
PDD          
n=37 
 
Number (%) of patients with 
sustained orthostatic 
hypotension  Fisher’s Exact 
test: p=0·004 
5 (13) 13 (34)     
0·03 
10 (34)  
0·04 
14 (52)   
0·001 
18 (49)   
0·001 
AD vs. DLB: 0·20 
AD vs. PDD: 0·16 
DLB vs. PDD: 0·80 
Median time (seconds) for 
return of  systolic blood 
pressure to baseline (IQR)   
Cox regression: p=0·001 
16 (12–19)  20 (12–70) 
0·002 
18 (11–30) 
0·06 
36 (19–141) 
0·001 
23 (16–73) 
0·002 
AD vs. DLB: 0·29 
AD vs. PDD: 0·952 
DLB vs. PDD: 0·26 
 
Legend to Table 5 
P values in the left hand column give the result of the Fisher’s Exact test across all groups (Cox regression in the case of time to return to 
baseline systolic blood pressure on standing).  
Columns 3–6: show the prevalence (%) of sustained orthostatic hypotension by diagnosis, with χ2 test for patient groups in comparison with the 
control group and median time to return to baseline systolic blood pressure on standing (inter–quartile range) with comparison for patient groups 
with the control group by Cox regression. 
The results of other predefined contrasts are given in the right hand column.  
All significant results are shown in boldface. 
  23 
TABLE 6: CLINICAL AUTONOMIC FUNCTION TESTS (EWING CLASSIFICATION) 
Legend to Table 6 
It was not possible to classify all participants, as some were unable to complete sufficient autonomic tests to enable the Ewing classification to 
be calculated. Participants with dementia were less likely to have sufficient results to determine Ewing classification than were controls, but 
there were no differences between patient groups. 
Diagnosis (n) CONTROL (34) AD (31) VAD (19) DLB (22) PDD (30)  
Normal  29 19 9 10 5  
Early (n) 5 8 8 6 14  
Atypical (n) 0 1 1 1 4  
Definite (n) 0 1 0 5 2  
Severe (n) 0 2 1 0 5  
Atypical, definite or severe 
autonomic neuropathy (n 
(%))Fisher’s Exact test: p<0·001 
0 (0) 4 (13) 2 (11) 6 (27) 11 (37) AD vs. DLB p=0·19    
AD vs. PDD p=0·03 
DLB vs. PDD p=0·48 
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DISCUSSION 
This is the first controlled study of autonomic function in AD, VAD, DLB and PDD 
in comparison with healthy controls. The findings, based upon a range of clinical 
autonomic tests and sensitive research tools, emphasise the importance of autonomic 
dysfunction in dementia. There were significant differences in severity of 
cardiovascular autonomic dysfunction between the four types of dementia. PDD and 
DLB had considerable dysfunction. VAD showed limited evidence of autonomic 
dysfunction, and in AD, apart from orthostatic hypotension, autonomic functions were 
relatively unimpaired. The prevalence of autonomic neuropathy as measured by the 
Ewing criteria was more common in all of the dementia sub types than in controls, but 
was especially prominent in PDD.  
PDD and DLB cases both showed evidence of parasympathetic dysfunction on 
clinical testing, and apart from the Valsalva ratio the degree of impairment was 
similar. However, on sympathetic testing, PDD patients were more impaired than 
DLB patients, although there was some evidence of sympathetic dysfunction in DLB 
in multivariate analyses. Both AD and VAD patients had a higher prevalence of 
sustained orthostatic hypotension and autonomic neuropathy than controls, but in 
other group comparisons did not differ from controls.  
There has been considerable debate about the diagnostic concepts of PDD and DLB. 
It has been suggested that in PD Lewy body pathology begins in the brainstem and 
progresses to the neocortex.[25] However, there may be a different pattern of 
evolution in DLB, with  some studies suggesting that cerebrocortical pathology 
predominates in DLB,[26,27] although prominent Lewy body pathology is still 
evident in the brain stem, including the dorsal vagal nucleus.[28] In our study the 
profile of parasympathetic abnormalities in PDD and DLB suggest that there is 
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significant central autonomic involvement of the dorsal vagal nucleus in both 
conditions. Inevitably, the patients with PDD were taking a higher dose of levodopa, 
reflecting the duration of their disease. In comparisons between PDD and DLB, use of 
levodopa and dose are not constantly correlated, but the correlation is strong. 
Adjustment for levodopa use or dose in the multivariate analyses comparing PDD and 
DLB would therefore result in the significant differences being lost. However, this 
does not necessarily mean that differences between PDD and DLB were solely due to 
the pharmacological effect of levodopa. It is more likely that they are measuring a 
similar variable, namely the extent of brainstem disease, as opposed to cortical disease. 
 
The origin of sympathetic dysfunction in Lewy body diseases has been thought to be 
mainly due to peripheral sympathetic denervation.[29] Cardiac 123I–Meta–
iodobenzylguanidine scintigraphy and neuropathological studies have found evidence 
of cardiac sympathetic denervation in Parkinson’s disease and DLB.[30,31] Lewy 
body pathology can also be found in medullary regions controlling preganglionic 
sympathetic neurons, but with relative preservation of catecholaminergic neuronal 
populations.[32] Our findings suggest that sympathetic dysfunction is present in PDD 
and DLB, but less marked in DLB patients. This raises the possibility that there may a 
differential susceptibility and order of involvement of central and peripheral 
autonomic neurons to Lewy body pathology in DLB and PDD. This needs to be 
addressed in comparative neuropathological studies of the autonomic nervous system, 
but highlights a potentially important pathological difference between the two 
conditions.   
The increased frequency of autonomic neuropathy in all dementias emphasises the 
importance of these conditions in all people with dementia. Their impact upon key 
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symptoms such as dizziness, syncope, falls, constipation and incontinence needs to be 
investigated. Specifically, the current study identifies an increased prevalence of 
orthostatic hypotension in all dementias. Although orthostatic blood pressure 
responses can be impaired for a number of reasons including medications, endothelial 
dysfunction and age related orthostatic hypotension, our findings remained significant 
after adjusting for age, gender, duration of dementia, hypertension, diabetes and 
cardiovascular medications, suggesting that autonomic dysfunction was possibly an 
attributable cause of orthostatic hypotension in these patients. No studies have 
compared the effects of sustained orthostatic hypotension upon the risk of falls in 
different types of dementia. Our findings highlight the importance of orthostatic 
hypotension in all patients with dementia and the need for further research into 
sustained orthostatic hypotension as a modifiable risk factor for falls. In elderly 
people without cognitive impairment, simple measures such as adequate hydration, 
support hosiery and pharmacological treatments such as fludrocortisone and 
midodrine can be used to manage orthostatic hypotension, as part of a multifactorial 
intervention to reduce the risk of falls.[33] Trials of multifactorial falls interventions 
for people with mild to moderate dementia are a priority.   
Cholinergic dysfunction has been discussed as a potential cause of autonomic failure 
in dementia patients, and may be particularly important in PDD and DLB, where 
cholinergic deficits are especially pronounced, and where the disease pathology 
involves the dorsal vagal nucleus. In this context, it will be important to determine the 
impact of cholinesterase inhibitor therapy in dementia patients with autonomic 
impairment. Preliminary reports do suggest an adverse effect of donepezil upon 
autonomic function, leading to carotid sinus hypersensitivity and falls in some 
individuals.[34] The general impact of cholinesterase inhibitors upon autonomic 
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function is difficult to determine from the existing clinical trial literature, given the 
selected nature of the patient populations, but will be important to establish for 
clinical practice where patients are frailer and more likely to have autonomic 
symptoms. 
The study included an appropriately aged control group, which is of importance 
because autonomic function declines with age.[35] Although the controls were 
slightly older than the PDD group (mean difference 3.9 +/-1.4 years), this strengthens 
the finding that dysautonomia is most impaired in PDD, as it is likely that even 
greater differences would have been found if the PDD cases were compared with 
younger controls. Unfortunately, the VAD group were slightly older than the control 
group (mean difference 3.9 +/-1.6 years), and this leads to some uncertainty with 
respect to the findings in this group. The abnormalities in the heart rate responses to 
standing and Valsalva manoeuvre may not have been present if comparisons had been 
made with an older control group. In addition some of the responses to the Ewing 
tests might not have been classified as abnormal or borderline if they were compared 
to a more closely age matched control group, with the result that the prevalence of 
autonomic neuropathy could have been overestimated. Nevertheless, the number of 
abnormal findings in our VAD group was few, and therefore we are able to conclude 
that there is not substantial dysautonomia in VAD, and that comparison with an older 
control group would be likely to improve the strength of this finding. 
We conclude that autonomic dysfunction can occur in all common dementias in older 
people, but is a particularly common feature of DLB and PDD. The high prevalence 
of autonomic neuropathy and sustained orthostatic hypotension in dementia has 
potentially important implications for patient management.  
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